Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents

被引:0
作者
Nozawa-Kobayashi, Mai [1 ,2 ,3 ]
Sakuma, Hidenobu [1 ,2 ]
Kanemaru, Hiroko [4 ]
Kurokawa, Akira [4 ]
Soga, Marie [4 ]
Yamashita, Moe [4 ]
Niimi, Kanae [5 ]
Kobayashi, Tadaharu [1 ,2 ]
机构
[1] Niigata Univ, Fac Dent, Div Reconstruct Surg Oral & Maxillofacial Reg, Niigata, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[3] Minamiuonuma City Yukiguni Yamato Hosp Dent Pediat, Minamiuonuma, Japan
[4] Niigata Univ Med & Dent Hosp, Oral Management Clin Med Cooperat, Niigata, Japan
[5] Niigata Univ, Med & Dent Hosp, Patient Support Ctr, Niigata, Japan
来源
ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG | 2024年 / 28卷 / 02期
关键词
Bone-modifying agents; Medication-related osteonecrosis of the jaw; Extraction; Quality of life; BISPHOSPHONATE-RELATED OSTEONECROSIS; ZOLEDRONIC ACID; BREAST-CANCER; POSITION PAPER; RISK-FACTORS; DOUBLE-BLIND; PHASE-III; PAMIDRONATE; METASTASES; PREVENTION;
D O I
10.1007/s10006-024-01221-6
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective This study aimed to verify whether tooth extraction before the administration of bone-modifying agents (BMA) was effective in preventing the onset of medication-related osteonecrosis of the jaw (MRONJ). Materials and methods This retrospective study included patients with a history of receiving BMA for cancer treatment. The patients were classified into three groups based on the timing of tooth extraction: no tooth extraction before the onset of MRONJ, tooth extraction before the administration of BMA, and tooth extraction after the administration of BMA. The incidence of MRONJ was compared between the groups. Fisher's exact test and Bonferroni correction were used to test for differences in proportions between the three groups. Results The total number of subjects was 123. Twenty-four patients (19.5%) developed MRONJ. The incidence rates were 12.3% (10/81), 17.9% (5/28), and 64.3% (9/14) in the non-extraction group, the extraction before BMA administration group, and the extraction after BMA administration group, respectively, showing statistically significant differences between the extraction after BMA administration group and the non-extraction groups and between the extraction after BMA administration group and the extraction before BMA administration group (p < 0.001, p = 0.0049). On the other hand, there was no statistically significant difference in incidence between the non-extraction and the extraction before BMA administration group (p = 0.5274). Conclusions Tooth extraction before the administration of BMA is effective in preventing the onset of MRONJ in patients receiving BMA for cancer treatment. Prevention of MRONJ development in patients receiving BMA for cancer treatment contributes to the maintenance of patients' quality of life.
引用
收藏
页码:849 / 857
页数:9
相关论文
共 31 条
[1]   Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases [J].
Aapro, Matti ;
Saad, Fred ;
Costa, Luis .
ONCOLOGIST, 2010, 15 (11) :1147-1158
[2]   Risk Factors for Osteonecrosis of the Jaws: a Case-Control Study from the CONDOR Dental PBRN [J].
Barasch, A. ;
Cunha-Cruz, J. ;
Curro, F. A. ;
Hujoel, P. ;
Sung, A. H. ;
Vena, D. ;
Voinea-Griffin, A. E. .
JOURNAL OF DENTAL RESEARCH, 2011, 90 (04) :439-444
[3]   American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].
Berenson, JR ;
Hillner, BE ;
Kyle, RA ;
Anderson, K ;
Lipton, A ;
Yee, GC ;
Biermann, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736
[4]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[5]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[6]   Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].
Fizazi, Karim ;
Carducci, Michael ;
Smith, Matthew ;
Damiao, Ronaldo ;
Brown, Janet ;
Karsh, Lawrence ;
Milecki, Piotr ;
Shore, Neal ;
Rader, Michael ;
Wang, Huei ;
Jiang, Qi ;
Tadros, Sylvia ;
Dansey, Roger ;
Goessl, Carsten .
LANCET, 2011, 377 (9768) :813-822
[7]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092
[8]   A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? [J].
Hasegawa, T. ;
Kawakita, A. ;
Ueda, N. ;
Funahara, R. ;
Tachibana, A. ;
Kobayashi, M. ;
Kondou, E. ;
Takeda, D. ;
Kojima, Y. ;
Sato, S. ;
Yanamoto, S. ;
Komatsubara, H. ;
Umeda, M. ;
Kirita, T. ;
Kurita, H. ;
Shibuya, Y. ;
Komori, T. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (08) :2465-2473
[9]   Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate [J].
Hortobagyi, GN ;
Theriault, RL ;
Lipton, A ;
Porter, L ;
Blayney, D ;
Sinoff, C ;
Wheeler, H ;
Simeone, JF ;
Seaman, JJ ;
Knight, RD ;
Heffernan, M ;
Mellars, K ;
Reitsma, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2038-2044
[10]   Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma [J].
Jeon, Ha-Lim ;
Oh, In-Sun ;
Baek, Yeon-Hee ;
Yang, Hyowon ;
Park, Jeehye ;
Hong, Soojung ;
Shin, Ju-Young .
JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (02) :254-263